Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Gains from Investment Securities: 2021-2025

Historic Gains from Investment Securities for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -$2,338.

  • ProQR Therapeutics N.V's Gains from Investment Securities fell 101.53% to -$2,338 in Q3 2025 from the same period last year, while for Sep 2025 it was $329,222, marking a year-over-year decrease of 21.09%. This contributed to the annual value of -$2.2 million for FY2021, which is 2219.68% down from last year.
  • ProQR Therapeutics N.V's Gains from Investment Securities amounted to -$2,338 in Q3 2025, which was up 98.01% from -$117,724 recorded in Q2 2025.
  • ProQR Therapeutics N.V's 5-year Gains from Investment Securities high stood at $4.2 million for Q1 2022, and its period low was -$879,346 during Q1 2021.
  • Its 3-year average for Gains from Investment Securities is $172,621, with a median of $152,653 in 2024.
  • In the last 5 years, ProQR Therapeutics N.V's Gains from Investment Securities skyrocketed by 2,647.99% in 2023 and then plummeted by 156.06% in 2025.
  • Quarterly analysis of 5 years shows ProQR Therapeutics N.V's Gains from Investment Securities stood at -$579,993 in 2021, then skyrocketed by 99.30% to -$5,041 in 2022, then surged by 2,647.99% to $128,454 in 2023, then climbed by 18.84% to $152,653 in 2024, then slumped by 101.53% to -$2,338 in 2025.
  • Its Gains from Investment Securities was -$2,338 in Q3 2025, compared to -$117,724 in Q2 2025 and $296,631 in Q1 2025.